Related Experiment Video

Updated: Jul 7, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.4K

Non-Coding RNAs and the Development of Chemoresistance to Docetaxel in Prostate Cancer: Regulatory Interactions and

Elena Pudova1, Anastasiya Kobelyatskaya1, Marina Emelyanova1

  • 1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.

Life (Basel, Switzerland)
|December 23, 2023
PubMed

Insights

Taxane chemotherapy is standard for advanced cancers, but resistance develops. This review explores how non-coding RNAs contribute to taxane resistance in prostate cancer and their prognostic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Taxane-based chemotherapy is a cornerstone treatment for advanced cancers.
  • Tumor cells frequently develop resistance to taxane therapy, limiting treatment efficacy.
  • The molecular mechanisms underlying taxane resistance are complex and not fully understood.

Purpose of the Study:

  • To review the role of non-coding RNAs in the development of taxane chemoresistance.
  • To highlight the prognostic potential of non-coding RNAs in prostate cancer.
  • To explore machine learning approaches for studying non-coding RNAs in drug resistance.

Main Methods:

  • Literature review of experimental studies on non-coding RNAs and chemoresistance.
  • Analysis of findings related to non-coding RNA expression and function.
  • Discussion of machine learning applications in non-coding RNA research.

Main Results:

  • Non-coding RNAs, including microRNAs and long non-coding RNAs, are implicated in taxane resistance.
  • Specific non-coding RNAs show prognostic value in prostate cancer patients undergoing taxane therapy.
  • Machine learning offers novel avenues for identifying and understanding regulatory roles of non-coding RNAs.

Conclusions:

  • Non-coding RNAs are critical regulators in the development of taxane chemoresistance.
  • Targeting specific non-coding RNAs may offer new therapeutic strategies for overcoming resistance.
  • Further research, aided by machine learning, is needed to fully elucidate the role of non-coding RNAs in cancer drug resistance.
Keywords:
chemoresistancecircRNAsdeep learningdocetaxelexosomeslncRNAsmachine learningmicroRNAsprostate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K